242 related articles for article (PubMed ID: 29042204)
21. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
23. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico.
Ortiz AP; Tortolero-Luna G; Romaguera J; Pérez CM; González D; Muñoz C; González L; Marrero E; Suárez E; Palefsky JM; Panicker G; Unger ER
Papillomavirus Res; 2018 Jun; 5():109-113. PubMed ID: 29555601
[TBL] [Abstract][Full Text] [Related]
24. Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.
Chow EPF; Fairley CK; Zou H; Wigan R; Garland SM; Cornall AM; Atchison S; Tabrizi SN; Chen MY
Clin Infect Dis; 2022 Aug; 75(2):323-329. PubMed ID: 34971362
[TBL] [Abstract][Full Text] [Related]
25. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
27. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
[TBL] [Abstract][Full Text] [Related]
29. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients.
de Araujo MR; Rubira-Bullen IR; Santos CF; Dionísio TJ; Bonfim CM; De Marco L; Gillio-Tos A; Merletti F
Oral Dis; 2011 Sep; 17(6):572-6. PubMed ID: 21332606
[TBL] [Abstract][Full Text] [Related]
31. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
34. Seroprevalence of human papillomavirus 6, 11, 16, and 18 in young primiparous women in Sao Paulo, Brazil.
Rama CH; Villa LL; Pagliusi S; Andreoli MA; Costa MC; Thomann P; Longatto-Filho A; Eluf-Neto J
Int J Gynecol Cancer; 2010 Nov; 20(8):1405-10. PubMed ID: 21051985
[TBL] [Abstract][Full Text] [Related]
35. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
36. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
Dauner JG; Pan Y; Hildesheim A; Harro C; Pinto LA
Vaccine; 2010 Jul; 28(33):5407-13. PubMed ID: 20591543
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
Coseo SE; Porras C; Dodd LE; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2011 Oct; 38(10):976-82. PubMed ID: 21934576
[TBL] [Abstract][Full Text] [Related]
40. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]